Untitled

Abstract

234 ALI = acute lung injury; AQP = aquaporin; ARDS = acute respiratory distress syndrome; FiO 2 = fractional inspired concentration of oxygen; IL = interleukin; PaO 2 = partial pressure of oxygen; TNF-α = tumor necrosis factor alpha. Critical Care August 2004 Vol 8 No 4 Groshaus et al. IntroductionAcute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are important because of the continued high mortality and costs of care of these conditions. Beta adrenergic agonists are inexpensive and are actually often used in the treatment of patients who have ALI or ARDS for reasons not related to attempts to improve resolution of lung injury. For example, inhaled beta-2 adrenergic agonists are used to decrease airway resistance when it is increased in ALI and ARDS. Intravenously infused beta adrenergic agonists are used when the circulation requires inotropic support because of shock or ventricular dysfunction, both of which are common in ALI and ARDS. It is unknown whether beta adrenergic agonists used for these other reasons also improve the resolution of ALI.We have chosen to focus on the evidence that beta-2 adrenergic agonists act through three mechanisms (increased clearance of salt and water from alveoli, anti-inflammatory effects, and bronchodilation) to improve the pathophysiology, and possibly the rate and success of resolution, of pulmonary edema and ALI. This leads to the hypothesis that beta-2 adrenergic agonists may be beneficial therapy for patients with ALI or with ARDS. DefinitionsDifferent definitions and scoring systems have been developed since the "adult respiratory distress syndrome" was first described by Ashbaugh and colleagues in 12 patients in 1967 [1]. The most current consensus conference definition of ALI is acute onset of acute respiratory failure characterized by PaO 2 /FiO 2 ≤300 mmHg, bilateral infiltrates, and pulmonary capillary wedge pressure AbstractAcute lung injury (ALI) and the acute respiratory distress syndrome are complex syndromes because both inflammatory and coagulation cascades cause lung injury. Transport of salt and water, repair and remodeling of the lung, apoptosis, and necrosis are additional important mechanisms of injury. Alveolar edema is cleared by active transport of salt and water from the alveoli into the lung interstitium by complex cellular mechanisms. Beta-2 agonists act on the cellular mechanisms of pulmonary edema clearance as well as other pathways relevant to repair in ALI. Numerous studies suggest that the beneficial effects of beta-2 agonists in ALI include at least enhanced fluid clearance from the alveolar space, anti-inflammatory actions, and bronchodilation. The purposes of the present review are to consider the effects of beta agonists on three mechanisms of improvement of lung injury: edema clearance, anti-inflammatory effects, and bronchodilation. This update reviews specifically the evidence on the effects of beta-2 agonists in human ALI and in models of ALI. The available evidence suggests that beta-2 agonists may be efficacious t...

High Cell-Free DNA Predicts Fatal Outcome among Staphylococcus aureus Bacteraemia Patients with Intensive Care Unit Treatment

“…Along with the cell-free DNA as a biomarker, procalcitonin and interleukin-10 have been investigated as promising biomarkers for patients with bacteraemia or sepsis. Recently, procalcitonin was presented as a predictor for endocarditis in SAB [43] and proposed to be a superior predictor for sepsis [20] , [44] . To the best of our knowledge, no reports have investigated the prognostic value of procalcitonin solely in SAB patients.…”

Prognostic and diagnostic value of procalcitonin in the post-transplant setting after liver transplantation

“…In the vast majority of cases, patients under immunosuppression did not show clinical signs of infection, such as fever, hypothermia, or tachycardia, and if these were present, they did not have any relevant specific diagnostic power, as they might indicate for example an impairment of the graft function such as an acute rejection episode [ 7 ]. Furthermore, well-established biochemical inflammation markers, such as C-reactive protein (CRP) or leucocyte count (LC), cannot immediately lead to the diagnosis of an infectious complication, whereby the early establishment of diagnosis is the most crucial stage in the management of such a patient population [ 3 , 8 ].…”

“…Procalcitonin (PCT) is identified as a diagnostic marker for infectious or septic processes and correlates better with its severity than CRP [ 3 , 8 – 13 ]. Procalcitonin is an acute phase protein, composed of 116 amino acids, and is the precursor of calcitonin.…”

Procalcitonin as an adjunctive biomarker in sepsis

“…[2] Furthermore, there are concerns about possible blood culture–negative clinical sepsis, particularly in the setting of increased prophylactic and empirical antibiotic use. [3] Conversely, differentiating true infection from contamination after growth of common skin commensals in blood cultures, poses a diagnostic problem.…”